Zhejiang Cheng Yi Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 603811.SS

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2023: USD 94.60 M

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. Revenue is USD 94.60 M for the year ending December 31, 2023, a -0.33% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2022 was USD 94.91 M, a -13.10% change year over year.
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2021 was USD 109.22 M, a -5.97% change year over year.
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2020 was USD 116.15 M, a 18.73% change year over year.
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2019 was USD 97.82 M, a 23.28% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 603811.SS

Zhejiang Cheng Yi Pharmaceutical Co., Ltd.

CEO	Mr. Chunjian Zhao
IPO Date	March 15, 2017
Location	China
Headquarters	No. 118, Chemical Road
Employees	738
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. produces and sells APIs and capsules/tablets in China. The company was formerly known as Wenzhou No. 3 Pharmaceutical Factory and changed its name to Zhejiang Cheng Yi Pharmaceutical Co., Ltd. in April 2001. Zhejiang Cheng Yi Pharmaceutical Co., Ltd. was founded in 1966 and is headquartered in Wenzhou, China.

Key trends

Past 5 years